Investor Ideas adds New #Stocks
in Cannabis (CSE: $MXT.C) (CSE: $PRMO.C), Biotech (Nasdaq: $IPHA, $VIR, $BNRX, $FREQ)
and Tech (CSE: $AMPD.C) (CSE: $TKR.C)
Point Roberts WA, Delta BC, November 1, 2019 –
(Investorideas.com Newswire) Investorideas.com, a global news source and
leading investor resource announces its weekly roundup of stocks added to its global stock
directories in cannabis, biotech and tech.
This week’s new cannabis companies are both
CSE-listed and are involved in CO2 extraction and financing for the
cannabis industry, respectively.
The latest biotech/life sciences companies are all
October Nasdaq IPOs.
The newest tech companies are both CSE-listed and
are involved in cloud computing and IoT & AI, respectively.
New Cannabis Companies:
MedXtractor Corp. (CSE:MXT) is a
Calgary-based company that manufactures patented, proprietary small-scale
carbon dioxide-based extractors that are used to extract essential oils and
compounds from a variety of botanical materials. At present, the Corporation
targets the "Craft" cannabis grower. Craft growers are those whose
crop is up to 800 indoor-sized plants per crop cycle. In management's opinion,
CO2 Extractors represent the state-of-the-art for high-potency, high-purity
oils, one of the fastest growing segments of the overall cannabis market.
Cannabis oils can be extracted from flowers (bud), trim (leaves) and/or
post-pressed rosin "chips" (leftovers from hydraulic press
extraction). The ongoing worldwide legalization of cannabis is underpinning the
rapidly growing demand for cannabis products with major growth seen in oils due
to their utility as feedstock for various ingestion methods. The Corporation
owns the patents on its CO2 Extractors.
Primo
Nutraceuticals Inc.
(CSE:PRMO) formerly
Bougainville Ventures Inc - provides strategic capital to the thriving cannabis
cultivation sector through ownership and development of commercial real estate
properties. We offer fully built out turnkey facilities equipped with
state-of-the-art growing infrastructure to cannabis growers and processors.
Cultivators lease these facilities and pay affordable fee-based management
costs to accelerate market entry and scalability. The first 10,000 square feet
of greenhouse space in Oroville, Washington has been completed and is ready for
occupancy. Our facilities remove financial barriers for cannabis cultivators as
traditional funding is limited due to United States federal laws and current
lending practices.
New Biotech Companies:
INNATE PHARMA SA (NasdaqGS: IPHA) is a commercial stage oncology-focused biotech
company dedicated to improving treatment and clinical outcomes for patients
through therapeutic antibodies that harness the immune system to fight cancer.
Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from
AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in
class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s
broad pipeline of antibodies includes several potentially first-in-class
clinical and preclinical candidates in cancers with high unmet medical need.
Innate Pharma has been a pioneer in the understanding of NK cell biology and
has expanded its expertise in the tumor microenvironment and tumor-antigens, as
well as antibody engineering. This innovative approach has resulted in a
diversified proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S,
Sanofi, and a multi-products collaboration with AstraZeneca.
VIR BIOTECHNOLOGY, INC. (NasdaqGS:VIR) is a
clinical-stage immunology company focused on combining immunologic insights
with cutting-edge technologies to treat and prevent serious infectious
diseases. Vir has assembled four technology platforms that are designed to
stimulate and enhance the immune system by exploiting critical observations of
natural immune processes. Its current development pipeline consists of five
product candidates targeting hepatitis B virus, influenza A, human
immunodeficiency virus and tuberculosis
BIONTECH SE (NasdaqGS:BNTX) was founded in
2008 on the understanding that every cancer patient’s tumor is unique and
therefore each patient’s treatment should be individualized. Its cutting-edge
pipeline includes individualized mRNA-based product candidates, innovative
chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted
cancer antibodies and small molecules. BioNTech has established relationships
with seven pharmaceutical collaborators, including Eli Lilly and Company,
Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group,
Genevant and Pfizer, and has published over 150 peer-reviewed publications on
its scientific approach.
FREQUENCY THERAPEUTICS, INC. (NasdaqGS:FREQ) is a leader in the
development of medicines designed to activate progenitor cells within the body
to treat degenerative diseases. The company’s progenitor cell activation (PCA)
approach stimulates progenitor cells to create functional tissue with the aim
of developing disease modifying therapies. The company’s lead product
candidate, FX-322, is designed to regenerate auditory hair cells to restore
hearing function. In a FX-322 Phase 1/2 study, the company observed
statistically significant and clinically meaningful improvement in key measures
of hearing function in patients with sensorineural hearing loss. The company is
evaluating additional diseases where its PCA approach could create functional
tissue, including a development program in multiple sclerosis. Headquartered in
Woburn, Mass., Frequency has a development and commercialization agreement with
Astellas Pharma Inc. for FX-322, for which it retains U.S. rights, as well as
additional collaboration agreements with academic and nonprofit research
organizations including The Scripps Research Institute, Massachusetts Eye and
Ear, and the Massachusetts Institute of Technology.
VIELA BIO, INC. (NasdaqGS:VIE) headquartered in
Gaithersburg, Maryland, is a clinical-stage biotechnology company pioneering
treatments for autoimmune and severe inflammatory diseases.
APREA THERAPEUTICS, INC. (NasdaqGS:APRE) is a
biopharmaceutical company headquartered in Boston, Massachusetts with research
facilities in Stockholm, Sweden, focused on developing and commercializing
novel cancer therapeutics that reactivate
mutant tumor suppressor protein, p53. The Company’s lead product candidate
is APR-246, a small molecule in clinical development for hematologic
malignancies, including myelodysplastic syndromes (MDS) and acute myeloid
leukemia (AML).
Neovasc, Inc. (TSX:
NVCN.TO; NASDAQ:
NVCN) is a specialty medical device company that
develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include Reducer, for the treatment of
refractory angina, which is not currently commercially available in the United
States and has been commercially available in Europe since 2015, and Tiara, for
the transcatheter treatment of mitral valve disease, which is currently under
clinical investigation in the United States, Canada, Israel and Europe.
New Tech Companies:
AMPD Ventures Inc. (CSE:AMPD) specializes
in providing high-performance cloud and compute solutions for low-latency
applications including video games and eSports, digital animation and visual
effects, and big data collection, analysis and visualization.
Tracker
Ventures Corp. (CSE:TKR) – formerly TrackLoop - is an analytics software
company that is leveraging digital asset technology to transform and modernize
multiple industries. TrackLoop is taking a diversified approach to the
analytics and technology space, delivering practical solutions in the finance,
logistics, cannabis, and pharmaceutical industries. The Company’s turnkey
real-time tracking solutions offer the very latest in IoT and AI, providing valuable
data and business intelligence to some of the world’s leading brands.
The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.
About Investorideas.com - News
that Inspires Big Investing Ideas Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports
biotech, water, renewable energy and more. Investor Idea’s original branded
content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis
News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk
and possible losses. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Disclosure is posted for each compensated news release, content published
/created if required but otherwise the news was not compensated for and was
published for the sole interest of our readers and followers. Contact
management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news
services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, PR and social media
services at Investorideas.com
To sponsor a daily podcast for the month or to be an expert guest please
contact us!
Contact
Investorideas.com
800-665-0411
No comments:
Post a Comment